Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Link to XBRL Interactive Data 30 June 2018

September 3, 2018 Kerry Rowe

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v

Post navigation

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Related Posts

European Commission approves Orphan Designation for Alterity’s lead drug candidate

January 14, 2020May 19, 2021

Prana receives A$3.3 million R&D Tax Incentive

March 18, 2019

PBT434 drug candidate shows potential as “next-generation” disease-modifying treatment in Parkinson’s Disease

July 17, 2013

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065